TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12419410

Group type: EXPERIMENTAL
Intervention: Confectionery snack
Number of subjects: 21

Group type: COMPARATOR
Intervention: Noncalorie snack
Number of subjects: 21
Study: 10429835

Group type: EXPERIMENTAL
Intervention: Zanamivir administered by intravenous route (up to 600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanamivir administered by oral route
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanamivir administered by intranasal route
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanamivir administered by inhaled route (nebuliser and dry powder)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanamivir (all routes)
Number of subjects: 0
Study: 7751495

Group type: EXPERIMENTAL
Intervention: Treatment for depression (12 sessions)
Number of subjects: 0
Study: 2196036

Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Number of subjects: 616

Group type: COMPARATOR
Intervention: Deferral of vitrectomy for 1 year
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Early vitrectomy in type I diabetes group
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Early vitrectomy in type II diabetes group
Number of subjects: 616
Study: 393053

Group type: EXPERIMENTAL
Intervention: Bromocriptine, 2.5 mg twice a day
Number of subjects: 0
Study: 6418666

Group type: EXPERIMENTAL
Intervention: CO2-H+ stimulus with workload reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant ventilation (VE) with regulated PETCO2 and PETO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End-tidal clamps termination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreasing CO2
Number of subjects: 0
Study: 30811844

Group type: EXPERIMENTAL
Intervention: Secondary alveolar bone grafting
Number of subjects: 45
Study: 28991823

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 receptor antagonist
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 27581874

Group type: EXPERIMENTAL
Intervention: Transcatheter left atrial appendage occlusion (LAAO)
Number of subjects: 0
Study: 25489341

Group type: EXPERIMENTAL
Intervention: Rater training (brief frame-of-reference training)
Number of subjects: 242
Study: 22836295

Group type: EXPERIMENTAL
Intervention: Experimental group (n=60) - underwent 3 specific loads of different types, durations, and intensities
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 90
Study: 20669817

Group type: EXPERIMENTAL
Intervention: 8% strontium acetate dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 16246656

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (800 mcg)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 mcg)
Number of subjects: 442
Study: 11917285

Group type: EXPERIMENTAL
Intervention: Amifostine (340 mg/m2) plus RT
Number of subjects: 191

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 191
Study: 8110570

Group type: EXPERIMENTAL
Intervention: isoflurane 1.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: halothane 0.75%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: fentanyl 1 microgram kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: pooled data from all subjects
Number of subjects: 40
Study: 2675427

Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg twice daily for two years or until death
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 341363

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 or 300 mg every 6 hours)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31857014

Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) stimulation
Number of subjects: 303
Study: 27823977

Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)
Number of subjects: 160
Study: 23026548

Group type: EXPERIMENTAL
Intervention: BTDS 10 mcg/hour patches applied for seven days
Number of subjects: 37
Study: 21876308

Group type: EXPERIMENTAL
Intervention: Ceftriaxone and vitamin A
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ceftriaxone only
Number of subjects: 76
Study: 19797951

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study: 17852372

Group type: EXPERIMENTAL
Intervention: Prior warning
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lifting-induced fatigue
Number of subjects: 31

Group type: COMPARATOR
Intervention: Light callisthenic exercises
Number of subjects: 31
Study: 15485478

Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1ra levels
Number of subjects: 0
Study: 11074869

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 120
Study: 8792880

Group type: EXPERIMENTAL
Intervention: 30% oxygen in nitrogen (group 1, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100% oxygen (group 2, n = 12)
Number of subjects: 24
Study: 15374364

Group type: EXPERIMENTAL
Intervention: Idebenone (45 mg twice daily orally)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 3880997

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) with diuretic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) without diuretic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 31544803

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 30
Study: 30140327

Group type: EXPERIMENTAL
Intervention: Forced oscillation technique (FOT) with 200 mcg salbutamol by MDI
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Forced oscillation technique (FOT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bronchial reversibility test using FOT
Number of subjects: 106
Study: 26630309

Group type: EXPERIMENTAL
Intervention: Nitrate rich beverage (12.8 mmol nitrate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (Placebo)
Number of subjects: 10
Study: 25757036

Group type: EXPERIMENTAL
Intervention: SPORT surgical treatment
Number of subjects: 1323

Group type: COMPARATOR
Intervention: NSQIP surgical treatment
Number of subjects: 1323
Study: 23332717

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic hysterectomy (M-LPS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Single-port hysterectomy (LESS)
Number of subjects: 68
Study: 19557517

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 2449
Study: 18691725

Group type: EXPERIMENTAL
Intervention: Repetitive inurement exercises (painful stimulation) for 14 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy subjects performing sports without painful stimulation)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Repetitive inurement exercises
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 16541857

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Tongli (HT 5), Gongsun (SP 4), Neiting (ST 44), Hegu (LI 4)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine western medicine (VitB2, VitC)
Number of subjects: 74
Study: 14666760

Group type: EXPERIMENTAL
Intervention: Yuantong Capsule (YTC), 1 capsule orally, 3 times a day for 2 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hydergine, 2 mg orally, 3 times a day for 2 months
Number of subjects: 83
Study: 11190420

Group type: EXPERIMENTAL
Intervention: Meglitinide analogues (repaglinide and nateglinide)
Number of subjects: 0
Study: 8840849

Group type: EXPERIMENTAL
Intervention: Dofetilide 0.75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dofetilide 0.25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6372737

Group type: EXPERIMENTAL
Intervention: Low-dose apomorphine (0.75 mg subcutaneously)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29251245

Group type: EXPERIMENTAL
Intervention: Tailored telemonitoring
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 301
Study: 30227969

Group type: EXPERIMENTAL
Intervention: Honey plus oral acyclovir
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acyclovir alone
Number of subjects: 100
Study: 27997586

Group type: EXPERIMENTAL
Intervention: Syntometrine® administration
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Epidural use
Number of subjects: 316
Study: 25749598

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cancer wellness and education program
Number of subjects: 114
Study: 22819406

Group type: EXPERIMENTAL
Intervention: 60 shocks per minute (group 1)
Number of subjects: 206

Group type: COMPARATOR
Intervention: 120 shocks per minute (group 2)
Number of subjects: 206
Study: 20053811

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadodiamide
Number of subjects: 20
Study: 18682012

Group type: EXPERIMENTAL
Intervention: Lifestyle-change programme (increased exercise and diet change: either reduction in glycaemic load or reduced-fat diet)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-glycaemic-load diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 33
Study: 15718828

Group type: EXPERIMENTAL
Intervention: Proview eye pressure monitor (PEPM)
Number of subjects: 70
Study: 12581080

Group type: EXPERIMENTAL
Intervention: Topical 3% diclofenac in 2.5% hyaluronan gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (vehicle only, hyaluronan gel)
Number of subjects: 150
Study: 9862835

Group type: EXPERIMENTAL
Intervention: MRI for solid meal (SM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Scintigraphy for solid meal (SM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MRI for liquid meal (LM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Scintigraphy for liquid meal (LM)
Number of subjects: 8
Study: 8501574

Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG, 500 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG, 250 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG, 100 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard IVIG, 500 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard IVIG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GBS hyperimmune IVIG
Number of subjects: 20
Study: 3326679

Group type: EXPERIMENTAL
Intervention: Controlled-release hydralazine BID
Number of subjects: 29

Group type: COMPARATOR
Intervention: Immediate-release hydralazine TID
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controlled-release hydralazine QD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Beta-blocker (80 mg/day of nadolol)
Number of subjects: 29
Study: 30742378

Group type: EXPERIMENTAL
Intervention: Nefradoz 1 capsule 2 times a day (n=45)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 80
Study: 27784460

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment (cinobufacini injection, herbal decoction, and Chinese acupoint application)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: sCTLA-4 levels and treatment regimen
Number of subjects: 64
Study: 25886416

Group type: EXPERIMENTAL
Intervention: Bupivacaine group (3 mg bupivacaine + 10 ug fentanyl)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine group (20 mg lidocaine + 25 ug fentanyl)
Number of subjects: 50
Study: 23218184

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day FAc inserts
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.5 μg/day FAc inserts
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: FAc implants
Number of subjects: 44
Study: 22333199

Group type: EXPERIMENTAL
Intervention: Propofol TCI plus a low concentration of sevoflurane inhalation induction (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ketamine plus propofol TCI (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fentanyl plus propofol TCI (Group C)
Number of subjects: 90
Study: 19454182

Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 0
Study: 16682486

Group type: EXPERIMENTAL
Intervention: Western diet supplemented with wheat bran (24 g/day)
Number of subjects: 9
Study: 15129696

Group type: COMPARATOR
Intervention: 99mTc-TRODAT-1 SPET imaging
Number of subjects: 188
Study: 11413109

Group type: EXPERIMENTAL
Intervention: Tenovil 4 microg/kg QD
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Tenovil 8 microg/kg TIW
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 10450618

Group type: EXPERIMENTAL
Intervention: Memory-based intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 50
Study: 8002836

Group type: EXPERIMENTAL
Intervention: Silicone oil removal
Number of subjects: 222

Group type: COMPARATOR
Intervention: Silicone oil retention
Number of subjects: 222
Study: 2729168

Group type: EXPERIMENTAL
Intervention: Low-Cu fructose diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-Cu cornstarch diet
Number of subjects: 19
Study: 4699595

Group type: EXPERIMENTAL
Intervention: 20 mg betamethasone in saline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 11
Study: 31760462

Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 395
Study: 31188172

Group type: COMPARATOR
Intervention: Lidocaine plus 2 mL distilled water (Lido)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lidocaine plus 2 mL (8 mg) dexamethasone (Dexa)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lidocaine plus 2 mL (1 µg/kg) dexmedetomidine (Dexm)
Number of subjects: 75
Study: 28724657

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) 20 g/d, 118 kcal
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA; 60 mg Fe + 400 μg folic acid/d)
Number of subjects: 4011
Study: 26458895

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 14 days
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Aspirin 100 mg daily for 14 days
Number of subjects: 4400
Study: 23977723

Group type: EXPERIMENTAL
Intervention: Butyrylated high amylose maize starch (HAMSB) 20 g twice daily for 28 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low amylose maize starch (LAMS)
Number of subjects: 41
Study: 21944077

Group type: COMPARATOR
Intervention: Sedentary participants
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Old players
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Young players vs Old players
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sedentary vs Old players
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Young vs Old players
Number of subjects: 121
Study: 18006188

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg intravenously
Number of subjects: 77

Group type: COMPARATOR
Intervention: Metoclopramide 20 mg intravenously
Number of subjects: 77
Study: 16804032

Group type: EXPERIMENTAL
Intervention: Radiofrequency exposure (1,800 MHz, Specific Absorption Rate 2 W/kg) with mitogenic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 0
Study: 12951616

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UCA) 10 mg/kg/day until surgery, n=30
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group, n=42
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UCA) treatment duration
Number of subjects: 72
Study: 10981524

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula (Nan HA)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Extensively hydrolyzed casein formula (Nutramigen)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula (Profylac)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Exclusively breast-fed infants
Number of subjects: 478

Group type: COMPARATOR
Intervention: Infants fed extensively hydrolyzed formula (Nutramigen or Profylac)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Infants fed partially hydrolyzed formula (Nan HA)
Number of subjects: 478
Study: 9101380

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-supplementation follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression models
Number of subjects: 0
Study: 8240057

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 525

Group type: COMPARATOR
Intervention: Non-Heparin
Number of subjects: 525
Study: 3298408

Group type: EXPERIMENTAL
Intervention: Recombinant alpha-interferon treatment (doses ranging from 18 to 50 million units/m2, 3 times per week)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Recombinant alpha-interferon treatment (doses ranging from 2.5 to 10 million units/m2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Untreated carriers (control group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 44
Study: 29574606

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25828692

Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg pre-emptive administration)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Etoricoxib (post-operative treatment)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (pre-emptive administration)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (post-operative treatment)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Etoricoxib and Placebo (sensory perception)
Number of subjects: 103
Study: 25436273

Group type: EXPERIMENTAL
Intervention: 8-week stress management programme (diaphragmatic breathing, progressive muscle relaxation, guided imagery, twice a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not undergoing the stress management programme (control group)
Number of subjects: 60
Study: 23244805

Group type: EXPERIMENTAL
Intervention: Patient-reported frequency of hypoglycemia
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Objectively confirmed hypoglycemic events (0, ≥1)
Number of subjects: 3059
Study: 20184604

Group type: EXPERIMENTAL
Intervention: Synbiotic mixture (extensively hydrolysed formula with Bifidobacterium breve M‐16V and a galacto‐/fructooligosaccharide mixture)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (same formula without synbiotics)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Synbiotic mixture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18596069

Group type: EXPERIMENTAL
Intervention: HAART (group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No HAART (group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: HIV-uninfected (group 1)
Number of subjects: 120
Study: 16052595

Group type: EXPERIMENTAL
Intervention: Pramipexole 4.5 mg orally every evening
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 60
Study: 12296613

Group type: EXPERIMENTAL
Intervention: Galantamine (Reminyl®)
Number of subjects: 0
Study: 10403354

Group type: EXPERIMENTAL
Intervention: Antibiotics (erythromycin, doxycycline, trimethoprim/sulfamethoxazole)
Number of subjects: 8
Study: 8840339

Group type: EXPERIMENTAL
Intervention: Viewing a violent movie
Number of subjects: 20

Group type: COMPARATOR
Intervention: Viewing a neutral movie
Number of subjects: 20
Study: 1929761

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 52
Study: 7338577

Group type: EXPERIMENTAL
Intervention: Bumetanide (1 to 2 mg daily for three days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide (80 mg daily for three days)
Number of subjects: 20
Study: 31486406

Group type: EXPERIMENTAL
Intervention: Online coaching via real-time chat messages
Number of subjects: 793

Group type: COMPARATOR
Intervention: Self-guided program (control group)
Number of subjects: 793
Study: 29058111

Group type: EXPERIMENTAL
Intervention: BFR
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON
Number of subjects: 16
Study: 26049614

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prilocaine with felypressin
Number of subjects: 40
Study: 23876569

Group type: EXPERIMENTAL
Intervention: Meditation therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 102
Study: 21352592

Group type: EXPERIMENTAL
Intervention: MTX plus adalimumab
Number of subjects: 402

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 402
Study: 19697195

Group type: EXPERIMENTAL
Intervention: 100 mg natural micronised progesterone intravaginally once daily from 20‐24 weeks' gestation until 36 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no progesterone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 mg natural micronised progesterone intravaginally
Number of subjects: 100
Study: 17084030

Group type: EXPERIMENTAL
Intervention: Suprathel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omiderm
Number of subjects: 0
Study: 14704911

Group type: EXPERIMENTAL
Intervention: PHMB-based system
Number of subjects: 0

Group type: COMPARATOR
Intervention: PQ-based system
Number of subjects: 0
Study: 11694928

Group type: EXPERIMENTAL
Intervention: ACL-deficient knees
Number of subjects: 44

Group type: COMPARATOR
Intervention: ACL-intact knees
Number of subjects: 44